Papa Medical Inc. Reports 69.3% Revenue Growth to $14.7 Million in Q2 2025

Papa Medical Inc. reported significant financial growth in its latest 10-Q filing for the quarter ending June 30, 2025. The company achieved revenues of $14.7 million for the three months ended June 30, 2025, marking a 69.3% increase from $8.7 million in the same period last year. For the six months ending June 30, 2025, total revenues reached $32.6 million, an 88.2% increase compared to $17.3 million for the first half of 2024. The company's net income also saw substantial growth, rising 44% to $621,223 for the second quarter and 89.6% to $1.4 million for the first half of 2025.

The financial performance reflects a notable increase in sales volume, particularly in the Hemp cannabinoid E-vapors segment, which accounted for 91.3% of total revenues in the second quarter. The company attributed this growth to heightened demand and improved brand recognition, alongside the introduction of new products such as medical nebulizers. However, the gross profit margin slightly decreased to 24.8% from 24.9% year-over-year, primarily due to adjustments in product mix and increased costs associated with raw materials and manufacturing.

Operationally, Papa Medical reported a rise in total operating expenses, which increased to $2.7 million for the second quarter, up from $1.6 million in the prior year. This increase was driven by higher selling and marketing expenses, which rose by 65.8% to $1.7 million, and general and administrative expenses, which increased by 59.2% to $654,567. The company also expanded its workforce, contributing to the rise in operational costs. As of June 30, 2025, Papa Medical had a total of 20,000,000 shares outstanding, with basic and diluted earnings per share of $0.03 for the quarter.

In terms of liquidity, the company reported cash and cash equivalents of $1.2 million as of June 30, 2025, a decrease from $4.7 million at the end of 2024. The decrease in cash was primarily due to net cash used in operating activities, which totaled $3.3 million for the first half of 2025. The company anticipates that its existing cash balances and expected cash flows from operations will be sufficient to meet its working capital requirements for at least the next twelve months.

Looking ahead, Papa Medical aims to continue expanding its market presence and product offerings, particularly in the Hemp cannabinoid E-vapors sector. The company is also preparing for its initial public offering (IPO) in the United States, which it believes will enhance its growth potential and operational capabilities. The management remains optimistic about future revenue growth driven by increased customer demand and strategic product development initiatives.